Personalis updates valuation with a raised fair value to $11 per share driven by Medicare reimbursement for its NeXT Personal test and strong Q3 revenue performance. Analysts see durable revenue growth and clinical validation as key drivers.

CMS issues National Coverage Determination for FDA-approved renal denervation treatment under Coverage with Evidence Development for uncontrolled hypertension in Medicare patients.